NEW YORK (GenomeWeb) – Metabolon has raised $5 million in an extension of its Series E financing round.
The Durham, NC-based metabolomics firm disclosed the financing in a regulatory document filed with the US Securities and Exchange Commission on Thursday. A company spokesperson told GenomeWeb that the financing is an extension of the Series E round completed in January 2014 that brought in $15 million in a preferred stock offering and brings the total amount raised in the round to $20 million.
The proceeds will be used for general working purposes. According to the SEC document, four investors participated in the current financing, though the company spokesperson declined to identify them. Investors in the 2014 financing included Camden Partners, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght, Fulcrum Financial Partners, and Sumitomo.
The company's metabolomics-based platform is used for biomarker discovery and developing diagnostic tests for obesity-related diseases. Metabolon also markets laboratory-developed tests for monitoring patients who are at risk for developing diabetes and helping clinicians make treatment decisions.